169 related articles for article (PubMed ID: 27721154)
21. Imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1 decrease the parasite burden in mice with acute toxoplasmosis.
Moine E; Moiré N; Dimier-Poisson I; Brunet K; Couet W; Colas C; Van Langendonck N; Enguehard-Gueiffier C; Gueiffier A; Héraut B; Denevault-Sabourin C; Debierre-Grockiego F
Int J Parasitol; 2018 Jun; 48(7):561-568. PubMed ID: 29524527
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and antiviral activities of 3-aralkylthiomethylimidazo[1,2-b]pyridazine derivatives.
Galtier C; Mavel S; Snoeck R; Andreï G; Pannecouque C; Witvrouw M; Balzarini J; De Clercq E; Gueiffier A
Antivir Chem Chemother; 2003 Jul; 14(4):177-82. PubMed ID: 14582846
[TBL] [Abstract][Full Text] [Related]
23. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and biological evaluation of imidazopyridazine derivatives containing isoquinoline group as potent MNK1/2 inhibitors.
Bu H; Yuan X; Wu H; Zhou J; Zhang H
Bioorg Med Chem; 2021 Jun; 40():116186. PubMed ID: 33971490
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors.
Elagawany M; Ibrahim MA; Ali Ahmed HE; El-Etrawy ASh; Ghiaty A; Abdel-Samii ZK; El-Feky SA; Bajorath J
Bioorg Med Chem Lett; 2013 Apr; 23(7):2007-13. PubMed ID: 23453843
[TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors.
Ryu JW; Han SY; Yun JI; Choi SU; Jung H; Ha JD; Cho SY; Lee CO; Kang NS; Koh JS; Kim HR; Lee J
Bioorg Med Chem Lett; 2011 Dec; 21(23):7185-8. PubMed ID: 22001029
[TBL] [Abstract][Full Text] [Related]
27. Triazolopyridazine LRRK2 kinase inhibitors.
Franzini M; Ye XM; Adler M; Aubele DL; Garofalo AW; Gauby S; Goldbach E; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong A; Ren Z
Bioorg Med Chem Lett; 2013 Apr; 23(7):1967-73. PubMed ID: 23454015
[TBL] [Abstract][Full Text] [Related]
28. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.
Pogacic V; Bullock AN; Fedorov O; Filippakopoulos P; Gasser C; Biondi A; Meyer-Monard S; Knapp S; Schwaller J
Cancer Res; 2007 Jul; 67(14):6916-24. PubMed ID: 17638903
[TBL] [Abstract][Full Text] [Related]
29. Library-based discovery of DYRK1A/CLK1 inhibitors from natural product extracts.
Grabher P; Durieu E; Kouloura E; Halabalaki M; Skaltsounis LA; Meijer L; Hamburger M; Potterat O
Planta Med; 2012 Jun; 78(10):951-6. PubMed ID: 22673832
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3Kα inhibitors.
Bruel A; Logé C; Tauzia ML; Ravache M; Le Guevel R; Guillouzo C; Lohier JF; Oliveira Santos JS; Lozach O; Meijer L; Ruchaud S; Bénédetti H; Robert JM
Eur J Med Chem; 2012 Nov; 57():225-33. PubMed ID: 23063566
[TBL] [Abstract][Full Text] [Related]
31. 3-nitroimidazo[1,2-b]pyridazine as a novel scaffold for antiparasitics with sub-nanomolar anti-Giardia lamblia activity.
Zheng Y; Müller J; Kunz S; Siderius M; Maes L; Caljon G; Müller N; Hemphill A; Sterk GJ; Leurs R
Int J Parasitol Drugs Drug Resist; 2022 Aug; 19():47-55. PubMed ID: 35716585
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
Liu ZY; Wenzler T; Brun R; Zhu X; Boykin DW
Eur J Med Chem; 2014 Aug; 83():167-73. PubMed ID: 24956553
[TBL] [Abstract][Full Text] [Related]
33. A small-molecule cell-based screen led to the identification of biphenylimidazoazines with highly potent and broad-spectrum anti-apicomplexan activity.
Moine E; Denevault-Sabourin C; Debierre-Grockiego F; Silpa L; Gorgette O; Barale JC; Jacquiet P; Brossier F; Gueiffier A; Dimier-Poisson I; Enguehard-Gueiffier C
Eur J Med Chem; 2015 Jan; 89():386-400. PubMed ID: 25462254
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors.
Zhao L; Zhang Y; Dai C; Guzi T; Wiswell D; Seghezzi W; Parry D; Fischmann T; Siddiqui MA
Bioorg Med Chem Lett; 2010 Dec; 20(24):7216-21. PubMed ID: 21074424
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and evaluation of the anti parasitic activity of aromatic nitro compounds.
Lopes MS; de Souza Pietra RC; Borgati TF; Romeiro CF; Júnior PA; Romanha AJ; Alves RJ; Souza-Fagundes EM; Fernandes AP; de Oliveira RB
Eur J Med Chem; 2011 Nov; 46(11):5443-7. PubMed ID: 21940071
[TBL] [Abstract][Full Text] [Related]
36. Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors.
Lin XD; Yang HW; Ma S; Li WW; Zhang CH; Wang WJ; Xiang R; Li LL; Yang SY
Bioorg Med Chem Lett; 2015 Oct; 25(20):4534-8. PubMed ID: 26342867
[TBL] [Abstract][Full Text] [Related]
37. Research on heterocyclic compounds. XXXIII--Synthesis and analgesic activity of imidazo[1,2-b]pyridazine-2-acetic acid derivatives.
Luraschi E; Arena F; Sacchi A; Laneri S; Abignente E; D'Amico M; Berrino L; Rossi F
Farmaco; 1995 May; 50(5):349-54. PubMed ID: 7626170
[TBL] [Abstract][Full Text] [Related]
38. 3-Biphenylimidazo[1,2-a]pyridines or [1,2-b]pyridazines and analogues, novel Flaviviridae inhibitors.
Enguehard-Gueiffier C; Musiu S; Henry N; Véron JB; Mavel S; Neyts J; Leyssen P; Paeshuyse J; Gueiffier A
Eur J Med Chem; 2013 Jun; 64():448-63. PubMed ID: 23665801
[TBL] [Abstract][Full Text] [Related]
39. Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic Activity.
Di Pisa F; Landi G; Dello Iacono L; Pozzi C; Borsari C; Ferrari S; Santucci M; Santarem N; Cordeiro-da-Silva A; Moraes CB; Alcantara LM; Fontana V; Freitas-Junior LH; Gul S; Kuzikov M; Behrens B; Pöhner I; Wade RC; Costi MP; Mangani S
Molecules; 2017 Mar; 22(3):. PubMed ID: 28282886
[TBL] [Abstract][Full Text] [Related]
40. Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.
Dorsch D; Schadt O; Stieber F; Meyring M; Grädler U; Bladt F; Friese-Hamim M; Knühl C; Pehl U; Blaukat A
Bioorg Med Chem Lett; 2015 Apr; 25(7):1597-602. PubMed ID: 25736998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
